Acquired small cell lung cancer resistance to Chk1 inhibitors involves Wee1 up‐regulation
Open Access
- 15 December 2020
- journal article
- research article
- Published by Wiley in Molecular Oncology
- Vol. 15 (4) , 1130-1145
Abstract
Platinum‐based chemotherapy has been the cornerstone treatment for small cell lung cancer (SCLC) for decades, but no major progress has been made in the past 20 years with regard to overcoming chemoresistance. As the cell cycle checkpoint kinase 1 (Chk1) plays a key role in DNA damage response to chemotherapeutic drugs, we explored the mechanisms of acquired drug resistance to the Chk1 inhibitor prexasertib in SCLC. We established prexasertib resistance in two SCLC cell lines and found that DNA copy number, messengerRNA (mRNA) and protein levels of the cell cycle regulator Wee1 significantly correlate with the level of acquired resistance. Wee1 small interfering RNA (siRNA) or Wee1 inhibitor reversed prexasertib resistance, whereas Wee1 transfection induced prexasertib resistance in parental cells. Reverse phase protein microarray identified up‐regulated proteins in the resistant cell lines that are involved in apoptosis, cell proliferation and cell cycle. Down‐regulation of CDK1 and CDC25C kinases promoted acquired resistance in parental cells, whereas down‐regulation of p38MAPK reversed the resistance. High Wee1 expression was significantly correlated with better prognosis of resected SCLC patients. Our results indicate that Wee1 overexpression plays an important role in acquired resistance to Chk1 inhibition. We also show that bypass activation of the p38MAPK signaling pathway may contribute to acquired resistance to Chk1 inhibition. The combination of Chk1 and Wee1 inhibitors may provide a new therapeutic strategy for the treatment of SCLC.Keywords
This publication has 49 references indexed in Scilit:
- Coexpression and coregulation analysis of time-series gene expression data in estrogen-induced breast cancer cellAlgorithms for Molecular Biology, 2013
- Pathways for Genome Integrity in G2 Phase of the Cell CycleBiomolecules, 2012
- Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancerNature Genetics, 2012
- CDK7 and CCNH Are Components of CDK-Activating Kinase and Are Required for Meiotic Progression of Pig Oocytes1Biology of Reproduction, 2011
- Treatment with the Chk1 inhibitor G�6976 enhances cisplatin cytotoxicity in SCLC cellsInternational Journal of Oncology, 2011
- Targeting ATR and Chk1 kinases for cancer treatment: A new model for new (and old) drugsMolecular Oncology, 2011
- In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in GlioblastomaCancer Cell, 2010
- Chk1 promotes replication fork progression by controlling replication initiationProceedings of the National Academy of Sciences, 2010
- Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2Current Opinion in Cell Biology, 2009
- Replicon Clusters Are Stable Units of Chromosome Structure: Evidence That Nuclear Organization Contributes to the Efficient Activation and Propagation of S Phase in Human CellsJournal of Cell Biology, 1998